A Study Comparing the Benefits and Risks of Eltrombopag and Romiplostim in Patients with Immune Thrombocytopenia (ITP) in the Real World Setting

Trial Profile

A Study Comparing the Benefits and Risks of Eltrombopag and Romiplostim in Patients with Immune Thrombocytopenia (ITP) in the Real World Setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Romiplostim
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top